1. Home
  2. VTYX

VTYX

Ventyx Biosciences Inc.

Logo Ventyx Biosciences Inc.

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
.
-
-
%

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Founded: 2018 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 334.9M IPO Year: 2021
Target Price: $20.50 AVG Volume (30 days): 4.2M
Analyst Decision: Buy Number of Analysts: 9
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.30 EPS Growth: N/A
52 Week Low/High: $1.86 - $40.58 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: